Jean Jacques Bienaime bought $12k of KROS
director at Keros Therapeutics, Inc.. 1,000 shares at an average of $11.70, traded Apr 15, 2026, filed Apr 17, 2026.
Score components
- +15RoleDirector
- 0Trade size$12k at market
- +3Relative to holdingsHoldings up 13%
- +8Price context46% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.0%, 3m -8.8%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001221590-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | POpen-market purchase Common Stock10b5-1 | +1,000 | $11.70 | $12k | 8,450 | Apr 17, 2026 |
Related signals
Other insiders at Keros Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Keros Therapeutics, Inc. | Esther Cho Chief Legal Officer | $46k 4,485 shares | -11% | |
| 10Weak | Keros Therapeutics, Inc. | Charles W. Newton director | $5,675 551 shares | -4% | |
| 41Moderate | Keros Therapeutics, Inc. | Lorena Raquel Lerner Chief Scientific Officer | $37k 3,568 shares | -11% | |
| 30Weak | Keros Therapeutics, Inc. | Annita Tanini Corp. Controller & VP, Finance | $13k 1,224 shares | -3% | |
| 36Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $10k 1,000 shares | +5% | |
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $11k 1,000 shares | +6% | |
| 26Weak | Keros Therapeutics, Inc. | Jean Jacques Bienaime director | $10k 1,000 shares | +6% | |
| 10Weak | Keros Therapeutics, Inc. | Charles W. Newton director | $5,522 550 shares | -4% | |
| 20Weak | Keros Therapeutics, Inc. | Nima Farzan director | $28k 2,625 shares | -21% | |
| 20Weak | Keros Therapeutics, Inc. | Julius Knowles director | $28k 2,625 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.